Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
Commentary|Articles|August 14, 2023
Unpacking Regenerative Medicines and Start-Up Funding with Luis Alvarez
Author(s)Grant Playter
Luis Alvarez, PhD, founder of Theradaptive, candidly discusses how his regenerative therapy start-up evolved and secured start-up funding.
Advertisement
Luis Alvarez, PhD, is the founder of
Advertisement
Related to this article
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
Biora will test oral adalimumab via its BioJet capsule vs injection in healthy volunteers, with dosing from December 2026 and data in early 2027.
Boehringer Ingelheim will pay Sino Biopharmaceutical $358 million upfront and near-term for options on six biologic oncology programs, deepening a partnership that began in 2024.
A former CIA officer, Pacific Research Institute economists, and industry groups say Treasury's proposed COINS Act biotechnology restrictions are too broad, while the National Security Commission on Emerging Biotechnology backs the move. Comments are due December 7, 2026.
Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.
Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.
Teva will commercialize etanercept-ykro (Eticovo) and infliximab-abda, adding 2 TNF inhibitor biosimilars to US options for inflammatory diseases.
Advertisement
Advertisement
Trending on BioPharm International
1
Shilpa CDMO Commits $50 Million to Scale Peptide Capacity in India
2
Lonza to Acquire Merck KGaA’s US CDMO Business, Adding ADC, Viral Vector, and LNP Capacity
3
FDA Finalizes Potency Assurance Guidance for Cell and Gene Therapies
4
Policy Leaders Urge Treasury to Narrow Biotech Outbound Investment Rule
5